ReviewCurrent opinion in rheumatology2016
Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis.
Review in Current opinion in rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Treating connective tissue disease-associated interstitial lung disease - think outside the box: a perspective.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Extended autoantibody panel in Turkish patients with early-stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes.Immunity, inflammation and disease · 2023Article
- A case of anti-HMGCR myopathy in a patient with breast cancer and anti-Th/To antibodies.Oxford medical case reports · 2023Article
- Advanced Autoantibody Testing in Systemic Sclerosis.Diagnostics (Basel, Switzerland) · 2023Review
- Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond.Frontiers in immunology · 2021Review
- Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis.Journal of scleroderma and related disorders · 2020Review
- Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.International journal of molecular sciences · 2020Review
- A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study.Experimental and therapeutic medicine · 2020Article
- GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis.Current rheumatology reports · 2019Review
- Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?Arthritis research & therapy · 2019Article
- Anti-CENP-B and anti-TOPO-1-containing sera from systemic sclerosis-related diseases with Raynaud's phenomenon induce vascular endothelial cell senescence not via classical p53-p21 pathway.Clinical rheumatology · 2018Article
- The Utilization of Autoantibodies in Approaches to Precision Health.Frontiers in immunology · 2018Article
- Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach.Frontiers in physiology · 2018Review
- Recent Approaches To Optimize Laboratory Assessment of Antinuclear Antibodies.Clinical and vaccine immunology : CVI · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAt the time of diagnosis, systemic sclerosis (SSc) is often well established with significant irreversible tissue and organ damage. Definitions of 'early SSc' have been proposed, which include the presence of SSc-associated autoantibodies. In addition, functional autoantibodies that are believed to be involved in SSc pathogenesis need to be considered. In this review, recent advances in the diagnostic utility and pathogenic role of autoantibodies in early SSc are summarized. Moreover, we propose a clinical care pathway illustrating how autoantibody testing along with key clinical features can be used to make an earlier diagnosis of SSc. RECENT
findingsRecent evidence has helped to develop a clearer understanding of the natural history, early clinical features, and autoantibodies that are predictors of SSc. The role of functional autoantibodies is leading to innovative approaches to evidence-based interventions and therapies that are based on mechanisms of disease. SUMMARY: Despite substantial advances, the high morbidity and mortality that currently characterizes SSc can largely be attributed to a delay in diagnosis, gaps in our understanding of the role of autoantibodies in early disease, and limited effective therapeutic options. An early and accurate diagnosis of SSc and use of autoantibody testing embedded in evidence-based clinical care pathways will help improve SSc-associated clinical outcomes and healthcare expenditures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.